Nmpa grants marketing approval to the first co-developed ngs-based companion diagnostic for lung cancer in china

Guangzhou, china, oct. 10, 2024 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”), an innovative company in the field of precision oncology, and dizal, a global biopharmaceutical company focused on malignant tumors and immunological diseases, jointly announced that the companion diagnostic (cdx) for egfr exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through their collaboration, has been approved by the national medical products administration (nmpa) of china. this marks the first co-developed ngs-based cdx for lung cancer approved by nmpa since the release of the cdx guideline in china.
BNR Ratings Summary
BNR Quant Ranking